Key Financial Figures

Income Statement (INR Crore):

  • Total Income from Operations: ₹7,119 (Q1 FY26: ₹6,957)
  • EBITDA: ₹1,192 (16.7% of revenue) (Q1 FY26: ₹1,778, 25.6%)
  • PAT: ₹789 (11.1% margin) (Q1 FY26: ₹1,298)

Balance Sheet (INR Crore as of June 2026):

  • Equity: ₹34,443 (June 2025: ₹32,665)
  • Total Debt: ₹600 (includes lease liabilities and borrowings) (June 2025: ₹459)
  • Inventory: ₹6,714 (June 2025: ₹6,091)
  • Cash and Cash Equivalents: ₹10,094 (includes current investments, fixed deposits, margin deposits, excluding unclaimed dividend balances) (June 2025: ₹10,838)
  • Trade Receivables: ₹5,948 (June 2025: ₹6,254)
  • Trade Payables: ₹3,446 (June 2025: ₹3,093)
  • Net Tangible Assets: ₹7,889 (June 2025: ₹6,669)
  • Goodwill and Intangibles: ₹6,928 (June 2025: ₹5,138)
  • Net Cash Position: ₹9,494

Business Segment Performance

Quarterly Business-wise Sales Performance (INR Crore):

  • India (Rx + Gx + CHL^): ₹3,452 (Q1 FY26: ₹3,070), +12% YoY
  • North America: ₹1,532 (Q1 FY26: ₹1,933), -21% YoY
  • One Africa#: ₹977 (Q1 FY26: ₹871), +12% YoY
  • South Africa: ₹658 (Q1 FY26: ₹695), -5% YoY
  • Emerging Markets and Europe: ₹999 (Q1 FY26: ₹861), +16% YoY
  • API and Others: ₹160 (Q1 FY26: ₹222), -28% YoY

^ CHL – Cipla Health Limited | # Includes South Africa, North Africa, Sub-Saharan Africa and Cipla Global Access

Operational Highlights

One India Business:

  • Achieved highest-ever quarterly revenue with 12% YoY growth
  • Chronic mix improved to 60.4% (IQVIA MAT June'26)
  • Branded Prescription: Market growth of 15.4%, 183 bps higher than IPM
  • Strong double-digit growth in Respiratory, Urology, Cardiac, and Anti-diabetes therapies
  • Trade Generics: Healthy YoY growth with 3 new product launches
  • Consumer Health: Anchor brands (Nicotex, Omnigel, Cipladine) maintained leadership positions

North America:

  • Revenue: $162 million
  • Albuterol ranked No. 1 in US Albuterol MDI market with 21% market share (IQVIA week ending June 26, 2026)
  • Product launches: gVentolin (following regulatory approval), Nintedanib, and Dapagliflozin

One Africa:

  • South Africa Private Market secondary growth: 6.5% vs market growth of 5.7% (IQVIA MAT May'26)
  • Prescription business maintained No. 2 position

Emerging Markets and Europe:

  • Revenue growth: 5% YoY in USD terms
  • Uptick in both DTM and B2B categories with sustained margins

R&D and Financial Position

  • R&D investments: ₹486 crore (6.8% of sales), up 12.3% YoY
  • Increased product filings and development initiatives
  • Strong net cash position: ₹9,494 crore
  • Debt primarily comprises lease liabilities and working capital requirements

Management Commentary

Achin Gupta, MD and Global CEO, stated: "We are pleased to share that we continue to make considerable progress across our focused markets. In Q1FY27, we delivered global revenues of INR 7,119 Cr. Our One-India business grew at solid 12% YoY. Branded Prescription business delivered a robust growth, with key therapies outpacing the market... We expect continued sequential growth in North America, supported by upcoming product pipeline... Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front."

Additional Information

  • Market data sources: IQVIA MAT June'26, IQVIA MAT May'26, IQVIA week ending June 26, 2026
  • Earnings conference call scheduled for July 23, 2026, at 1600 hrs IST
  • Dial-in numbers provided for universal access and toll-free numbers for USA, UK, Hong Kong, and Singapore
  • Transcript of conference call will be available at www.cipla.com